BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 75,000 shares of the business's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $33.57, for a total transaction of $2,517,750.00. Following the sale, the chief executive officer now owns 5,023,447 shares in the company, valued at $168,637,115.79. This represents a 1.47 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Neil Kumar also recently made the following trade(s):
- On Wednesday, February 19th, Neil Kumar sold 31,543 shares of BridgeBio Pharma stock. The shares were sold at an average price of $36.14, for a total transaction of $1,139,964.02.
- On Tuesday, January 28th, Neil Kumar sold 326,932 shares of BridgeBio Pharma stock. The shares were sold at an average price of $36.29, for a total transaction of $11,864,362.28.
BridgeBio Pharma Stock Down 5.4 %
NASDAQ:BBIO traded down $1.89 during trading hours on Monday, hitting $33.01. 3,282,866 shares of the stock were exchanged, compared to its average volume of 3,176,007. The company's 50 day moving average is $32.79 and its two-hundred day moving average is $28.40. BridgeBio Pharma, Inc. has a twelve month low of $21.62 and a twelve month high of $39.47. The company has a market capitalization of $6.28 billion, a P/E ratio of -11.58 and a beta of 1.07.
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The business had revenue of $5.88 million during the quarter, compared to analysts' expectations of $4.04 million. On average, equities research analysts expect that BridgeBio Pharma, Inc. will post -3.67 EPS for the current year.
Wall Street Analysts Forecast Growth
BBIO has been the topic of several recent research reports. HC Wainwright restated a "buy" rating and set a $49.00 target price on shares of BridgeBio Pharma in a report on Thursday, February 13th. Cantor Fitzgerald reissued an "overweight" rating and set a $95.00 price objective on shares of BridgeBio Pharma in a research report on Friday, February 21st. Evercore ISI boosted their price objective on BridgeBio Pharma from $45.00 to $50.00 and gave the stock an "outperform" rating in a research report on Monday, December 23rd. Citigroup boosted their price objective on BridgeBio Pharma from $45.00 to $49.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Finally, Bank of America boosted their price objective on BridgeBio Pharma from $42.00 to $45.00 and gave the stock a "buy" rating in a research report on Monday, November 25th. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $51.67.
Get Our Latest Analysis on BridgeBio Pharma
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the stock. Jefferies Financial Group Inc. acquired a new position in shares of BridgeBio Pharma in the 4th quarter valued at $5,076,000. Mackenzie Financial Corp lifted its stake in shares of BridgeBio Pharma by 6.6% in the 4th quarter. Mackenzie Financial Corp now owns 9,505 shares of the company's stock valued at $261,000 after purchasing an additional 592 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of BridgeBio Pharma in the 4th quarter valued at $109,000. Frazier Life Sciences Management L.P. lifted its stake in shares of BridgeBio Pharma by 1.1% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,800,457 shares of the company's stock valued at $104,285,000 after purchasing an additional 40,000 shares during the period. Finally, Woodline Partners LP lifted its stake in shares of BridgeBio Pharma by 132.9% in the 4th quarter. Woodline Partners LP now owns 2,211,521 shares of the company's stock valued at $60,684,000 after purchasing an additional 1,261,772 shares during the period. Institutional investors and hedge funds own 99.85% of the company's stock.
BridgeBio Pharma Company Profile
(
Get Free Report)
BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
Featured Stories

Before you consider BridgeBio Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BridgeBio Pharma wasn't on the list.
While BridgeBio Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.